SD-208

• Description :

  SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  TGF-β Receptor

• Type :

  Reference compound

• Related Pathways :

  TGF-beta/Smad

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SD-208.html

• Purity :

  99.87

• Solubility :

  DMSO : 9.09 mg/mL (ultrasonic)

• Smiles :

  FC1=CC=C(Cl)C=C1C2=NC3=NC=CN=C3C(NC4=CC=NC=C4)=N2

• Molecular Formula :

  C17H10ClFN6

• Molecular Weight :

  352.75

• Precautions :

  H302

• References & Citations :

  [1]Uhl M, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004 Nov 1;64 (21) :7954-61.|[2]Ge R, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res. 2006 Jul 15;12 (14 Pt 1) :4315-30.|[3]Sun Y, et al. Inhibition of intimal hyperplasia in murine aortic allografts by the oral administration of the transforming growth factor-beta receptor I kinase inhibitor SD-208. J Heart Lung Transplant. 2014 Jun;33 (6) :654-61.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [627536-09-8]